The funding will support development for the company’s SB-1 Remedisc treatment, according to a March 28 news release. It is a seven-amino acid chain peptide and designed to decrease inflammation and maintain the structural integrity of the disc.
The funding was led by Viscogliosi Bros. Existing investors include Cercano Management and Pacira Biosciences.
